Skip to main content

Advertisement

SpringerLink
Log in

Botulinum Toxin A: Evolving Treatment Strategies for the Chronic Pelvic Pain Patient

  • Pelvic Pain (R Moldwin and S Bahlani, Section Editors)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Chronic pelvic pain syndrome (CPPS) is defined as pain perceived within the structures of the male or female pelvis of at least 6-month duration. The management of CPPS in both men and women poses a challenge to both the clinician and the patient. Botulinum toxin type A (BoNT-A) is known to block the release of neurotransmitters at the neuromuscular junction but also appears to have anti-nociceptive and anti-inflammatory effects. BoNT-A has been used for over two decades to treat conditions associated with pathological muscle hyperactivity. There is emerging evidence that BoNT-A may play a role in treating CPPS when alternate treatments and more conservative measures have been ineffective. Moving forward, well-designed clinical trials are needed to further investigate the utility of BoNT-A use in the treatment of CPPS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, are highlighted as: •• Of major importance

  1. Fall M, Baranowski AP, Fowler CJ, Lepinard V, Malone-Lee JG, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2004;46:681–9.

    Article  CAS  PubMed  Google Scholar 

  2. Moldwin RM. Similarities between interstitial cystitis and male chronic pelvic pain syndrome. Curr Urol Rep. 2002;3:313–8.

    Article  PubMed  Google Scholar 

  3. Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: are they related? Curr Urol Rep. 2006;7:329–34.

    Article  PubMed  Google Scholar 

  4. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1–9.

    Article  PubMed  Google Scholar 

  5. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–95.

    Article  CAS  PubMed  Google Scholar 

  6. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49:644–50.

    Article  CAS  PubMed  Google Scholar 

  7. Chuang YC, Yoshimura N, Wu M, Huang CC, Chiang PH, Tyagi P, et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol. 2007;51:1119–27.

    Article  CAS  PubMed  Google Scholar 

  8. Jhang JF, Kuo HC. Novel treatment of chronic bladder pain syndrome and other pelvic pain disorders by onabotulinumtoxinA injection. Toxins (Basel). 2015;7(6):2232–50.

    Article  CAS  Google Scholar 

  9. Allergan, Inc. Highlights of prescribing information. Available at http://www.allergan.com/assets/pdf/botox_pi.pdf, accessed, January16, 2016.

  10. Hanno PM, Erickson D, Moldwin R, Farday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53. Discusses most effective approach for patients/caretaker.

    Article  PubMed  Google Scholar 

  11. Konkle KS, Berry SH, Elliott MN, Hilton L, Suttorp MJ, Clauw DJ, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012;187(2):508–12.

    Article  PubMed  Google Scholar 

  12. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871–5.

    Article  PubMed  Google Scholar 

  13. Giannantoni A, Costantini E, di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49:704–9.

    Article  CAS  PubMed  Google Scholar 

  14. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657–61.

    Article  CAS  PubMed  Google Scholar 

  15. Kuo H.C., Jiang Y.H., Tsai Y.C., Kuo Y.C. Intravesical botulinum toxin-A injection reduce bladder pain of interstital cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double blind, placebo-controlled clinical trial. Neuroruol. Urodyn. 2015 epub ahead of print. Discusses the effectiveness of BoNT-A in the reduction of BP symptoms in patients with IC/BPS

  16. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008;179:1031–4.

    Article  CAS  PubMed  Google Scholar 

  17. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Phys. 2013;E15-23.

  18. Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189:548–53.

    Article  CAS  PubMed  Google Scholar 

  19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2013. 5th ed. Arlington, VA.

  20. Anastasiadis AG, Davis AR, Ghafar MA, Burchardt M, Shabsigh R. The epidemiology and definition of female sexual disorders. World J Urol. 2002;20(2):74–8.

    Article  PubMed  Google Scholar 

  21. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin. Lancet. 1997;349(9047):252–3.

    Article  CAS  PubMed  Google Scholar 

  22. Pacik PT. Vaginismus: review of current concepts and treatment using botox injections, bupivacaine injections, and progressive dilation with the patient under anesthesia. Aesthetic Plast Surg. 2011;35(6):1160–4.

    Article  PubMed  Google Scholar 

  23. Pelletier F, Parratte B, Penz S, Moreno JP, Aubin F, Humbert P. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol. 2011;164(3):617–22.

    CAS  PubMed  Google Scholar 

  24. Tieu KD, Macgregor JL. Successful treatment of vulvodynia with onabtulinum toxin A. Arch Dermatol. 2011;147(2):251–2.

    Article  PubMed  Google Scholar 

  25. Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med. 2006;51(6):467–70.

    CAS  PubMed  Google Scholar 

  26. Petersen CD, Giraldi A, Kristensen E, et al. Botulinum toxin type A: a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6(9):2523–37.

    Article  CAS  PubMed  Google Scholar 

  27. Moldwin RM, Fariello JY. Myofascial trigger points of the pelvic floor: associations with urologic pain syndromes and treatment strategies including injection therapy. Curr Urol Rep. 2013;14(5):4009–417.

    Article  Google Scholar 

  28. Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstruct Surg. 2013;19(5):288–92.

    Article  Google Scholar 

  29. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women. A randomized controlled trial. Obstet Gynecol. 2006;108(4):915–23.

    Article  PubMed  Google Scholar 

  30. Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O’Hare 3rd P, Botulinum WK, et al. Injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospected pilot study. Female Pelvic Med Reconst Surg. 2015;21(5):277–82.

    Article  Google Scholar 

  31. Thomson Angus JM, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type A (Botox®) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG. 2005;112(2):247–9.

    Article  CAS  PubMed  Google Scholar 

  32. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7.

    Article  CAS  PubMed  Google Scholar 

  33. Rees J, Abrahams M, Doble A, Cooper A, The Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–25.

    Article  CAS  PubMed  Google Scholar 

  34. El-enen MA, Abou-Farha M, El-Abd A, El-Tatawy H, Tawfik A, El-Abd S, et al. Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: the transurethral vs. transrectal approach. Arab J Urol. 2015;13(2):94–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Falahatkar S, Shahab E, Gholamjani MK, Kazemnezhad E. Transurethral intraprostatic injection of botulinum toxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study. BJU Int. 2015;116:641–9. Explains that the BoNT-A injections might serve as a therapeutic option in patients with CP/CPPS.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Thomas Jefferson University, 1025 Walnut Street Suite 1100, Philadelphia, PA, 19107, USA

    Whitney R. Smith, Alana M. Murphy, Akhil K. Das & Patrick J. Shenot

Authors
  1. Whitney R. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alana M. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akhil K. Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick J. Shenot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick J. Shenot.

Ethics declarations

Conflict of Interest

Drs Smith, Murphy, Das, and Shenot declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Pelvic Pain

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smith, W.R., Murphy, A.M., Das, A.K. et al. Botulinum Toxin A: Evolving Treatment Strategies for the Chronic Pelvic Pain Patient. Curr Bladder Dysfunct Rep 11, 277–283 (2016). https://doi.org/10.1007/s11884-016-0374-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-016-0374-3

Keywords

Search

Navigation